21:45 , Jul 12, 2019 |  BC Extra  |  Company News

July 12 Company Quick Takes: Emflaza could be cost-effective for DMD at highest threshold; plus Darzalex, Skyrizi, Forxiga

ICER gives Emflaza pricing more leeway in updated report  The Institute for Clinical and Economic Review released an updated evidence report on Duchenne muscular dystrophy therapies that increased its range of acceptable prices at which...
07:00 , Jul 18, 2016 |  BC Week In Review  |  Financial News

BliNK Biomedical financial update

BliNK Biomedical S.A.S. , Lyon, France   Business: Cancer, Antibodies   Date announced: 2016-07-12   Note: BliNK Biomedical raised EUR1.7 million ($1.8 million) in an additional close of a series A round, bringing the total...